E-DRUG: WHO EDL Committee 2004 and proposed deletions
-----------------------------------------------------
dear E-druggers,
The WHO/EDM web page for the EDL Committee
(http://www.who.int/medicines/organization/par/edl/expertcomm.shtml)
mentions 19-23 April 2004 as the next Committee meeting.
The 2003 report mentions the following existing essential drugs for review
for possible deletion at next meeting:
1.1 ether (review actual consumption)
2.2 codeine
2.3 colchicine
5.0 clonazepam
6.1.1 niclosamide
6.1.1 pyrantel,
6.1.3 triclabendazole
6.1.3 oxamniquine
6.2.1 imipenem/cilastatin
6.2.2 nalidixic acid
6.2.2 spectinomycin
6.2.4 levofloxacin
6.2.4 thioacetazone/isoniazid
6.6 diethyltoluamide
7.1 ergotamine
11.1 polygeline
11.2 Factor IX and factor VIII
12.2 isoprenaline
12.2 procainamide
12.2 quinidine
12.3 nifedepine
13.7 topical sun protection agent
17.3 local anaesthetic/astringent ointment
17.5 atropine
18.3.1 (and 18.7) medroxyprogesteron acetate
21.1 silver nitrate eye solution
22.1 ergometrine
22.2 salbutamol
25.1 aminophylline
25.1 cromoglicic acid
25.1 theophylline
27 calcium gluconate
27 sodium fluoride
The Committee recommended that these items be marked in the list with the
following footnote: "The efficacy and safety of this item or group has been
questioned and its continued inclusion on the list will be reviewed at the
next meeting of the Expert Committee".
E-drug welcomes debate on these proposals. Anyone who wants to motivate for
keeping any of the above?
regards
Wilbert Bannenberg
E-drug moderator
Email: wilbertb at freeler.nl [due to increasing spam loads, please repair
email]
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug